These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 22889147)

  • 61. Integrase combination effective.
    AIDS Patient Care STDS; 2006 Sep; 20(9):658. PubMed ID: 16987052
    [No Abstract]   [Full Text] [Related]  

  • 62. Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trial.
    Gallien S; Braun J; Delaugerre C; Charreau I; Reynes J; Jeanblanc F; Verdon R; de Truchis P; May T; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    J Antimicrob Chemother; 2011 Sep; 66(9):2099-106. PubMed ID: 21712241
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of raltegravir in HIV-1 management.
    Rokas KE; Bookstaver PB; Shamroe CL; Sutton SS; Millisor VE; Bryant JE; Weissman SB
    Ann Pharmacother; 2012 Apr; 46(4):578-89. PubMed ID: 22496475
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Dynamic escape of pre-existing raltegravir-resistant HIV-1 from raltegravir selection pressure.
    Codoñer FM; Pou C; Thielen A; García F; Delgado R; Dalmau D; Santos JR; Buzón MJ; Martínez-Picado J; Alvarez-Tejado M; Clotet B; Ruiz L; Paredes R
    Antiviral Res; 2010 Dec; 88(3):281-6. PubMed ID: 20883724
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact on health-related quality of life of a switch from enfuvirtide to raltegravir among multidrug-resistant HIV-1-infected patients: a randomized open-label trial (EASIER-ANRS 138).
    Boulet T; Pavie J; Charreau I; Braun J; Reynes J; Morlat P; Piroth L; Spire B; Molina JM; Aboulker JP;
    HIV Clin Trials; 2010; 11(5):283-93. PubMed ID: 21126958
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Once-daily raltegravir moving ahead.
    Fernández-Montero JV
    AIDS Rev; 2013; 15(4):238-9. PubMed ID: 24322385
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [The newest developments in anti-HIV-1 drugs].
    Zhang XQ
    Yao Xue Xue Bao; 2010 Feb; 45(2):194-204. PubMed ID: 21351429
    [TBL] [Abstract][Full Text] [Related]  

  • 68. HIV treatment and the nonclinician: getting your bearings.
    HRSA Careaction; 2007 Jan; ():1-12. PubMed ID: 17380596
    [No Abstract]   [Full Text] [Related]  

  • 69. First-line raltegravir. No evidence of comparative effectiveness.
    Prescrire Int; 2010 Nov; 19(110):248-50. PubMed ID: 21284354
    [TBL] [Abstract][Full Text] [Related]  

  • 70. How individual can personalized antiretroviral treatment be? Deep salvage in an HIV-1-infected patient.
    Jensen B; Esser S; Kaiser R; Luebke N; Häussinger D
    Intervirology; 2012; 55(2):167-71. PubMed ID: 22286888
    [TBL] [Abstract][Full Text] [Related]  

  • 71. [Genetic barrier to antiretroviral drug-resistance. Focus on raltegravir, the first integrase inhibitor].
    Delaugerre C
    Med Mal Infect; 2010 Sep; 40 Suppl 1():S1-10. PubMed ID: 20800182
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The prevalence of antiretroviral multidrug resistance in highly active antiretroviral therapy-treated patients with HIV/AIDS between 2004 and 2009 in South Korea.
    Choi JY; Kwon OK; Choi BS; Kee MK; Park M; Kim SS
    J Clin Virol; 2014 Jun; 60(2):154-60. PubMed ID: 24680255
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial.
    De Castro N; Braun J; Charreau I; Pialoux G; Cotte L; Katlama C; Raffi F; Weiss L; Meynard JL; Yazdanpanah Y; Delaugerre C; Madelaine-Chambrin I; Aboulker JP; Molina JM;
    Clin Infect Dis; 2009 Oct; 49(8):1259-67. PubMed ID: 19757993
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Raltegravir: a review of its use in the management of HIV infection in treatment-experienced patients.
    Croxtall JD; Keam SJ
    Drugs; 2009 May; 69(8):1059-75. PubMed ID: 19496631
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A case of apparent resistance to all available antiretroviral drugs in a HIV-positive patient.
    Chibo D; Roth N; Birch C
    Sex Health; 2010 Mar; 7(1):82-4. PubMed ID: 20152102
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.
    Elbasha EE; Szucs T; Chaudhary MA; Kumar RN; Roediger A; Cook JR; Opravil M
    HIV Clin Trials; 2009; 10(4):233-53. PubMed ID: 19723611
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An examination of drug-drug interactions with raltegravir.
    Edmunds-Ogbuokiri J
    HIV Clin; 2010; 22(2):12-15. PubMed ID: 20806800
    [No Abstract]   [Full Text] [Related]  

  • 78. Pharmacokinetics of and short-term virologic response to low-dose 400-milligram once-daily raltegravir maintenance therapy.
    Ananworanich J; Gorowara M; Avihingsanon A; Kerr SJ; van Heesch N; Khongpetch C; Uanithirat A; Hill A; Ruxrungtham K; Burger DM;
    Antimicrob Agents Chemother; 2012 Apr; 56(4):1892-8. PubMed ID: 22252825
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure.
    Marcelin AG; Delaugerre C; Beaudoux C; Descamps D; Morand-Joubert L; Amiel C; Schneider V; Ferre V; Izopet J; Si-Mohamed A; Maillard A; Henquell C; Desbois D; Lazrek M; Signori-Schmuck A; Rogez S; Yerly S; Trabaud MA; Plantier JC; Fourati S; Houssaini A; Masquelier B; Calvez V; Flandre P;
    Int J Antimicrob Agents; 2013 Jul; 42(1):42-7. PubMed ID: 23562640
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Pharmacokinetics and interactions of raltegravir].
    Placeres Alsina MM; Tuset Creus M; Miró JM
    Enferm Infecc Microbiol Clin; 2008 Nov; 26 Suppl 12():23-8. PubMed ID: 19572422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.